Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialys
Go back to Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialys| Oppenheimer Rising Dividends Fund, Inc. Class A (NASDAQ: ARDX) | Delayed: 3.80 +0.03 (0.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.77 | 52 Week High | $20.98 | |||
| Open | $3.73 | 52 Week Low | $6.36 | |||
| Day High | $3.92 | P/E | N/A | |||
| Day Low | $3.69 | EPS | $0.00 | |||
| Volume | 4,458,062 | |||||
